10-08-2025
Santen Pharmaceutical Co (SNPHF) was downgraded to a Hold Rating at Jefferies
Jefferies analyst Stephen Barker downgraded Santen Pharmaceutical Co to a Hold on August 8 and set a price target of Yen1,700.00. The company's shares closed last Wednesday at $11.45.
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Barker covers the Healthcare sector, focusing on stocks such as Sumitomo Dainippon Pharma Co, Eisai Co, and Otsuka Holdings Co. According to TipRanks, Barker has an average return of 10.6% and a 52.63% success rate on recommended stocks.
Currently, the analyst consensus on Santen Pharmaceutical Co is a Moderate Buy with an average price target of $14.56.
Based on Santen Pharmaceutical Co's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $77.23 billion and a net profit of $8.78 billion. In comparison, last year the company earned a revenue of $79.13 billion and had a net profit of $29 million
